estrogens conjugated, Premarin
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: conjugated estrogens
BRAND NAME: Premarin
DRUG CLASS AND MECHANISM: Estrogens are one of the two major classes of female hormones. (Progestins comprise the second major class). Estrogens are used primarily to treat the symptoms of menopause and states in which there is a deficiency of estrogen, for example, in women who have had their ovaries removed. Conjugated estrogens are a mixture of several different estrogens (estrogen salts) that are derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate.
Estrogens have widespread effects on many tissues in the body. Estrogens cause growth and development of the female sexual organs and maintain female sexual characteristics such as the growth of underarm and pubic hair, body contours, and skeleton. Estrogens also increase secretions from the cervix and growth of the inner lining of the uterus (endometrium).
GENERIC AVAILABLE: No.
PREPARATIONS: Tablets: 0.3, 0.45, 0.625, 0.9, and 1.25 mg. Vaginal cream: 0.625 mg per gm of cream. Injection: 25 mg per vial
STORAGE: Conjugated estrogen tablets and cream should be stored at room temperature, between 15-30 C (59-86 F). The injection should be stored between 2-8 C (36-46 F).
PRESCRIBED FOR: Conjugated estrogens are used for treating the symptoms of menopause including hot flashes, vaginal dryness, and vaginal atrophy. If used solely for treating vaginal dryness and vaginal atrophy, the cream is preferred. They also are used as therapy when the body does not produce enough estrogen due to female castration (removal of the ovaries), ovarian failure or underdevelopment of hormone-secreting organs (hypogonadism).
Conjugated estrogens also are used for treating advanced prostate cancer in selected men and women with metastatic breast cancer. Although estrogens are approved for preventing osteoporosis, other non-estrogen medications are preferred for this purpose. Intravenous conjugated estrogens are used for treating abnormal uterine bleeding due to hormonal imbalance.
DOSING: To minimize side effects, the lowest effective oral dose of conjugated estrogens is used. The usual starting dose for treating symptoms associated with menopause and for preventing postmenopausal osteoporosis is 0.3 mg/day. The dose should be increased based on response.
Conjugated estrogens may be administered continuously or in a cyclical fashion (i.e., 25 days on treatment then 5 days off treatment).
Hypogonadism is treated cyclically with doses of 0.3 mg or 0.625 mg daily for 25 days followed by 5 days off treatment.
The dose for women who have had their ovaries removed or have ovarian failure is 1.25 mg daily for three weeks followed by one week off treatment. In reality, most women take estrogens continuously since during the week off treatment, symptoms return because of the lack of estrogen.
For treatment of breast cancer, the recommended dose is 10 mg daily for three months. Abnormal uterine bleeding due to hormonal imbalance is treated with one 25 mg intravenous or intramuscular injection. Another injection may be given in 6-12 hours if needed.
The vaginal cream is used for treating vulvar and vaginal atrophy, and the recommended dose is ½ to 2 g daily.
DRUG INTERACTIONS: Estrogens increase the liver's ability to manufacture factors that promote the clotting of blood. Because of this, patients receiving warfarin (Coumadin), a drug that thins the blood and prevents clotting by reducing clotting factors, need to be monitored for loss of the blood thinning effect if treatment with an estrogen is begun.
Rifampin (Rifadin), barbiturates, carbamazepine (Tegretol), griseofulvin (Grifulvin), phenytoin (Dilantin), St. John's wort, and primidone all increase the elimination of estrogen by enhancing the liver's ability to eliminate estrogens. Use of any of these medications with estrogens may result in a reduction of the beneficial effects of estrogens.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index